ritonavir   Click here for help

GtoPdb Ligand ID: 8804

Abbreviated name: RTV
Synonyms: A-84538 | ABBOTT-84538 | ABT 538 | ABT-538 | Norvir®
Approved drug PDB Ligand
ritonavir is an approved drug (EMA & FDA (1996))
Compound class: Synthetic organic
Comment: Ritonavir is an orally bioavailable antiviral that is generally administered in combination with other anti-HIV or anti-HCV drugs.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ritonavir

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 11
Hydrogen bond donors 4
Rotatable bonds 22
Topological polar surface area 202.26
Molecular weight 720.31
XLogP 3.94
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(NC(C(CC(Cc1ccccc1)NC(=O)C(C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1
Isomeric SMILES O=C(N[C@H]([C@H](C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1
InChI InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1
InChI Key NCDNCNXCDXHOMX-XGKFQTDJSA-N
References
1. Fontana E, Dansette PM, Poli SM. (2005)
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Curr Drug Metab, 6 (5): 413-54. [PMID:16248836]
2. Kharasch ED, Mitchell D, Coles R, Blanco R. (2008)
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
Antimicrob Agents Chemother, 52 (5): 1663-9. [PMID:18285471]
3. Zeldin RK, Petruschke RA. (2004)
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.
J Antimicrob Chemother, 53 (1): 4-9. [PMID:14657084]
4. Zhou J, Tracy TS, Remmel RP. (2011)
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
Drug Metab Dispos, 39 (2): 322-9. [PMID:21030469]